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Abstract: 300 words  
Title:  How are pain treatment response rates in primary care influenced by co-prescription of 
CYP2D6 inhibitors? 
Authors: Rhys Pockett, Caroline O’Leary, Pippa Anderson, Ahmed Nasser, Thomas Winfield, David 
Ansell 
Objectives: To determine the rates of co-prescription of CYP2D6-inhibiting medications with pain 
medication and the impact on response rates to pain medications, in the UK primary care setting. 
Methods: Codeine and tramadol are prodrugs requiring activation by the CYP2D6 enzyme. These 
drugs may have limited effectiveness when co-prescribed with other medications known to inhibit 
the CYP2D6 pathway. This contrasts with CYP2D6-independent analgesia, e.g. buprenorphine, which 
do not require CYP2D6 activation. 
We identified the co-prescription of three study pain medications; buprenorphine, codeine and 
tramadol with CYP2D6-inhibiting drugs including amitriptyline and fluoxetine. Patients aged ≥18 
years with chronic non-malignant pain and prescribed buprenorphine, codeine or tramadol between 
01/01/2009 and 31/01/2013 were identified in The Health Improvement Network (THIN) database.  
Patients were excluded if they had history of; chronic kidney disease stage 4/5, cancer, neuropathic 
pain, sciatica/radiculopathy, diabetes, back pain or a prior prescription for a study drug. Patients 
were classified as responders if they were either “cured” (discontinued treatment) or stable 
(remained on treatment), or a non-responder if they were referred to a pain clinic or switched to a 
CYP2D6-independent analgesic.  Multivariate logistic regression was used to identify the predictors 
of response and estimate the influence of CYP2D6-inhibitors. 
Results: The cohort consisted of 43,632 patients: 90.8% were responders, and CYP2D6-inhibiting 
drugs were prescribed to 33.8% of the cohort.  Almost three times as many patients failed to 
respond in those prescribed a CYP2D6-inhibitor (16% vs. 6%). Controlling for medication, 
demographics and co-morbidities the logistic regression indicated the odds of responding for those 
with a CYP2D6-inhibiting co-prescription were 39% lower than those without a co-prescription for a 
CYP2D6 inhibiting drug (OR= 0.61, 95% CI 0.57 to 0.66). 
Conclusion: Chronic non-malignant pain patients with a co-prescription for a CYP2D6-inhibiting 
medication were significantly less likely to respond to analgesia treatment and therefore received 
suboptimal pain management.   
 
 
